Form 8-K - Current report:
SEC Accession No. 0001558370-24-015726
Filing Date
2024-11-14
Accepted
2024-11-14 16:24:55
Documents
17
Period of Report
2024-11-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K fbio-20241114x8k.htm   iXBRL 8-K 39015
2 EX-99 fbio-20241114xex99.htm EX-99 360671
3 GRAPHIC fbio-20241114xex99001.jpg GRAPHIC 12064
  Complete submission text file 0001558370-24-015726.txt   621477

Data Files

Seq Description Document Type Size
4 EX-101.SCH fbio-20241114.xsd EX-101.SCH 4835
5 EX-101.DEF fbio-20241114_def.xml EX-101.DEF 14893
6 EX-101.LAB fbio-20241114_lab.xml EX-101.LAB 13027
7 EX-101.PRE fbio-20241114_pre.xml EX-101.PRE 15200
19 EXTRACTED XBRL INSTANCE DOCUMENT fbio-20241114x8k_htm.xml XML 7276
Mailing Address 1111 KANE CONCOURSE SUITE 301 BAY HARBOR ISLANDS FL 33154
Business Address 1111 KANE CONCOURSE SUITE 301 BAY HARBOR ISLANDS FL 33154 781-652-4500
Fortress Biotech, Inc. (Filer) CIK: 0001429260 (see all company filings)

EIN.: 205157386 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35366 | Film No.: 241462891
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)